Gambling DisorderMOGADORNCT06981546
Modeling Clinical Outcomes in Gambling Addiction
An observational study of Gambling Disorder, run by Hospices Civils de Lyon at 9 sites in France.
Trial summary
Gambling disorder (GD) is recognized as an addictive disorder. Financial consequences of GD are often dramatic, inducing professional, familial, legal and medical repercussions and particularly mental health consequences. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gambling Disorder
- How many people
- 268 participants
- Where
- 9 sitesFrance
- Study dates
- 1 Sep 2025to 1 Sep 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 268 patients with gambling disorder according to DSM-5 criteria newly managed in one of the participating centers or who had an interruption in management of more than 6 months.
Who may be able to join
- Patient, male or female, over 18 years old, consulting in one of the participating centers.
- DSM-5 criteria for gambling disorder at inclusion: at least 4 criteria present in the 12 months preceding the study.
- First treatment for gambling disorder or no treatment in the last 6 months (initiation or re-initiation of care).
Who cannot join
- Unable to be reached by phone.
- Unable to use the internet.
- Patient under antiparkinsonian treatment of the dopaminergic family.
- Being treated with a drug that may trigger/increase symptoms of gambling disorder (e.g. dopamine agonist).
- Subject under guardianship.
Trial locations and contacts
9 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Pauline DROUIN contact
9 sites in 1 country
France9 sites
Hôpital Jen Minjoz, CHU de Besançon
Besançon, 25030
Julie GIUSTINIANI, MD,PhD, jgiustiniani@chu-besancon.fr
Julie GIUSTINIANI
Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier
Bron, 69500
Benjamin ROLLAND, MD, PhD, benjamin.rolland@univ-lyon1.fr
Benjamin ROLLAND
Service Universitaire d'Addictologie de Lyon (SUAL), Groupement Hospitalier Est
Bron, 69500
Véronique FONTEILLE, MD, PhD, 04 72 11 80 64, veronique.fonteille@chu-lyon.fr
Véronique FONTEILLE
Service Universitaire d'Addictologie, CHU de Clermont-Ferrand
Clermont-Ferrand, 63000
Georges BROUSSE, MD, PhD, gbrousse@chu-clermontferrand.fr
Georges BROUSSE
Name of location * Service d'Addictologie, Groupe Hospitalier Seclin Carvin
Lille, 59000
Pierre TAQUET, Psychologist, PhD, pierre.taquet@chu-lille.fr
Pierre TAQUET
Centre Expert Régional du Jeu Pathologique (CERJeP Limousin)
Limoges, 87000
Philippe NUBUKPO, MD, philippe.nubukpo@9online.fr
Philippe NUBUKPO
Service Universitaire d'Addictologie, CHU de Nîmes
Nîmes, 30000
Amandine LUQUIENS, amandine.luquiens@chu-nimes.fr
Amandine LUQUIENS
Assistance Publique des Hôpitaux de Paris, Hôpital Marmottan
Paris, 75017
Thomas GAON, MD, t.gaon@ghu-paris.fr
Thomas GAON
Hôpital de Bellevue, CHU de St-Etienne
Saint-Etienne, 42000
Aurélia GAY, MD, PhD, aurelia.gay@chu-st-etienne.fr
Aurélia GAY
About this study
Gambling disorder (GD) is recognized as an addictive disorder. Financial consequences of GD are often dramatic, inducing professional, familial, legal and medical repercussions and particularly mental health consequences.
MOGADOR is a longitudinal, multicentric, prospective, prognostic study, which aims to identify factors predicting the evolution of french patients with GD in care centers particularly involved in the management of GD. The main goal will focus on evolution of DSM-5 (Diagnostic and Statistical Manual of Mental Disorder 5th edition) GD criteria during the first year of follow-up. The prognostic factors will be collected at base-line and they will be considered to influence the long-term prognosis of patients.
Read more
For patients suffering of GD, our main hypothesis is that initial factors like individual socio-demographic characteristics, clinical psychiatric profiles, addiction comorbidities, and behaviour are associated with the clinical prognosis (total remission of DSM-5 criteria of GD at 12 months).
MOGADOR will be the first study, aiming to model prognostic aspects of GB in populations specially monitored for this disorder.
- Conditions
- Gambling Disorder
- Keywords
- Gambling disorders, Modeling outcomes, Socio-demographic Characteristics, Clinical psychiatric profiles
- Medical subject headings
- Gambling
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with gambling disorder | OGADOR will focus exclusively on patients with DSM-5 criteria for gambling disorder and on demand for medical care. In this study psychiatric and addictological comorbidities, frequent in such a cohort, will constitute a specific inclusion factor, key characteristic leading an analysis of the impact on the patient prognosis. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Partial remission of gambling disorder at 12 months (strictly less than 4 DSM-5 criteria)
Assessment of DSM-5 criteria will be performed by the clinician, and by a previously trained CRA if clinical follow-up is discontinued.
Measured: DSM-5 criteria assessment will be conducted at 9 and 12 months after inclusion.
modeling prognostic factors
The prognostic factors, studied will be: number of initial DSM-5 criteria, gender, age, marital status, housing, employment status, socioeconomic level, time spent gambling, impulsivity, type of gambling, location of gambling, and also the factor with the strongest association in univariate analysis among the following factors:
- Depression (PHQ scale),
- Anxiety (GAD scale),
- Quality of life (SF-36 scale).
Measured: at inclusion visit.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2025
- Study start1 Sep 2025 (estimated)
- Primary completion1 Sep 2029 (estimated)
- Study completion1 Sep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gambling DisorderStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 268 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06981546
- Sponsor's protocol ID
- 69HCL21_0270
- Other IDs
- 2024-A01805-42
- Acronym
- MOGADOR
- Status last verified
- May 2025
- First submitted
- 5 May 2025
- Last updated
- 20 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Modeling Clinical Outcomes in Gambling Addiction
- ClinicalTrials.gov ID
- NCT06981546
- Acronym / sponsor ID
- MOGADOR / 69HCL21_0270
- Conditions
- Gambling Disorder
- Keywords
- Gambling disorders, Modeling outcomes, Socio-demographic Characteristics, Clinical psychiatric profiles
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 268 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 1 Sep 2025 (estimated)
- Primary completion
- 1 Sep 2029 (estimated)
- Study completion
- 1 Sep 2030 (estimated)
- First posted
- 20 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Gambling disorder (GD) is recognized as an addictive disorder. Financial consequences of GD are often dramatic, inducing professional, familial, legal and medical repercussions and particularly mental health consequences.
MOGADOR is a longitudinal, multicentric, prospective, prognostic study, which aims to identify factors predicting the evolution of french patients with GD in care centers particularly involved in the management of GD. The main goal will focus on evolution of DSM-5 (Diagnostic and Statistical Manual of Mental Disorder 5th edition) GD criteria during the first year of follow-up. The prognostic factors will be collected at base-line and they will be considered to influence the long-term prognosis of patients.
For patients suffering of GD, our main hypothesis is that initial factors like individual socio-demographic characteristics, clinical psychiatric profiles, addiction comorbidities, and behaviour are associated with the clinical prognosis (total remission of DSM-5 criteria of GD at 12 months).
MOGADOR will be the first study, aiming to model prognostic aspects of GB in populations specially monitored for this disorder.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with gambling disorder | – | –OGADOR will focus exclusively on patients with DSM-5 criteria for gambling disorder and on demand for medical care. In this study psychiatric and addictological comorbidities, frequent in such a cohort, will constitute a specific inclusion factor, key characteristic leading an analysis of the impact on the patient prognosis. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 268 patients with gambling disorder according to DSM-5 criteria newly managed in one of the participating centers or who had an interruption in management of more than 6 months.
Key inclusion criteria (3 listed)
- Patient, male or female, over 18 years old, consulting in one of the participating centers.
- DSM-5 criteria for gambling disorder at inclusion: at least 4 criteria present in the 12 months preceding the study.
- First treatment for gambling disorder or no treatment in the last 6 months (initiation or re-initiation of care).
Key exclusion criteria (5 listed)
- Unable to be reached by phone.
- Unable to use the internet.
- Patient under antiparkinsonian treatment of the dopaminergic family.
- Being treated with a drug that may trigger/increase symptoms of gambling disorder (e.g. dopamine agonist).
- Subject under guardianship.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Partial remission of gambling disorder at 12 months (strictly less than 4 DSM-5 criteria)
Time frame: DSM-5 criteria assessment will be conducted at 9 and 12 months after inclusion.
Assessment of DSM-5 criteria will be performed by the clinician, and by a previously trained CRA if clinical follow-up is discontinued.
modeling prognostic factors
Time frame: at inclusion visit.
The prognostic factors, studied will be: number of initial DSM-5 criteria, gender, age, marital status, housing, employment status, socioeconomic level, time spent gambling, impulsivity, type of gambling, location of gambling, and also the factor with the strongest association in univariate analysis among the following factors: * Depression (PHQ scale), * Anxiety (GAD scale), * Quality of life (SF-36 scale).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2025.
Related trials for Gambling Disorder
Not yet recruiting
Low-Intensity Focused Ultrasound for Gambling Disorder
Gambling Disorder, Gambling Addiction
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
RecruitingPhase 2
Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study
Gambling Disorder
Recruiting
Digital Cognitive Behavioral Therapy for Gambling Disorder
Gambling Disorder, Gambling
RecruitingObservational study
Is Craving a Central Criterion for Diagnosing a Behavioral Addiction?
Addictive Behaviors, Internet Addiction Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pauline DROUIN contact
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gambling Disorder, run by Hospices Civils de Lyon at 9 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Véronique FONTEILLE, MD, PhD (04 72 11 80 64, veronique.fonteille@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Partial remission of gambling disorder at 12 months (strictly less than 4 DSM-5 criteria) (time frame: DSM-5 criteria assessment will be conducted at 9 and 12 months after inclusion.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2025.